8
Jul
2026
Hana Pharm. Co., Ltd.
Exhibitor at CPHI South East Asia 2026 stand G49
About Us
Categories
-
Country/Region:Korea, Republic Of
-
On CPHI since:2025
-
Employees:500 - 999
Company types
Event information
CPHI South East Asia 2026
-
08 Jul 2026 - 10 Jul 2026
-
QSNCC, Bangkok, Thailand
-
Visit us at stand G49
Products Featured at CPHI South East Asia 2026
-
Product Dexmedetomidine HCI
-Active Ingredients: Dexmedetomidine HCI -Dosage: 200mcg/2mL -Indication Sedation under intensive care management Conscious sedation for non-intubated patients during surgery and procedures -GMP: Korea GMP -Stability: Zone IV b -
Product Isoflurane
-Active Ingredients: Isoflurane -Dosage: 100mL -Indication General anesthesia -GMP: Korea GMP -Stability: Zone IV b -
Product Propofol
-Active Ingredients: Propofol -Dosage: 120mg/12mL, 200mg/20mL -Indication Induction and maintenance of general anesthesia Sedation of ventilated patients receiving intensive care Sedation of surgical and diagnostic procedures -GMP: Korea GMP -Stability: Zone IV b -
Product Remimazolam
-Active Ingredients: Remimzaolam Bsylate -Excipients: Dextran 40, Lactose monohydrate, sodium hydroxide, hydrochloric acid -Dosage: 20mg, 50mg -Indication: 1. Byfavo Inj. 20mg The induction and maintenance of general anesthesia The induction and maintenance of procedural sedation in adults undergoing proce... -
Product Sevoflurane
-Active Ingredients: Sevoflurane -Dosage: 250mL -Indication General anesthesia -GMP: Korea GMP -Stability: Zone IV b
